May 27 (Reuters) - German drug vial maker Gerresheimer

on Monday announced an expansion of its U.S.

production site as it sees growing demand for weight-loss drugs,

including of the GLP-1 class.

The company is investing around 166 million euros ($180.24

million) in the construction of two buildings, creating 400 new

jobs in Peachtree.

The site produces autoinjectors, which can be used in

diabetes and obesity therapy, such as Novo Nordisk's

Wegovy and Eli Lilly Zepbound, among other medical

devices.

($1 = 0.9210 euros)